||Last Updated: Nov 17th, 2006 - 22:35:04
Monoclonal antibody recognizes a specific sugar on the surface of anthrax bacteria spores
Spores of the dreaded Bacillus anthracis have already been used as a bioweapon against the civilian population. Once inhaled, the anthrax pathogen almost always leads to death if the victims are not treated within 24 to 48 hours. Rapid and accurate diagnosis is thus vital. A team from the Swiss Federal Institute of Technology (ETH) in Zürich, the Swiss Tropical Institute, and the University of Bern has now developed a new immunological approach that can be used to specifically recognize anthrax spores.
Aug 18, 2006, 18:47
Scientists design functionalized liposome - a potent anthrax toxin inhibitor
Scientists funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have engineered a powerful inhibitor of anthrax toxin that worked well in small-scale animal tests. Led by NIAID grantees Ravi S. Kane, Ph.D., of Rensselaer Polytechnic Institute, in Troy, NY, and Jeremy Mogridge, Ph.D., of the University of Toronto, the investigators built a fatty bubble studded with small proteins that can cling tightly to the cell membrane receptor-binding protein used by anthrax toxin to gain entry into a host cell.
Apr 25, 2006, 21:20
PlyPH protein kills anthrax bacteria by exploding their cell walls
Not all biological weapons are created equal. They are separated into categories A through C, category A biological agents being the scariest: They are easy to spread, kill effectively and call for special actions by the pubic health system. One of these worrisome organisms is anthrax, which has already received its fair share of media attention. But work in Vince Fischetti’s laboratory at Rockefeller University suggests that a newly discovered protein could be used to fight anthrax infections and even decontaminate areas in which anthrax spores have been released.
Apr 22, 2006, 17:43
Surprising new insights about the acid pH levels required for anthrax toxin
Surprising new insights about the acid pH levels required for anthrax toxin to invade the cells of the body may help accelerate development of medications for the treatment of anthrax, a disease caused by a spore-forming bacterium.
Sep 7, 2005, 08:11
Diagnostic method for identifying Bacillus anthracis receives FDA approval
A method for identifying Bacillus anthracis, the causative agent of anthrax, has been cleared for diagnostic use by the U.S. Food and Drug Administration (FDA). The test, known as the Gamma Phage Assay, was modified by scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to improve its performance and reliability when used with clinical specimens. The original form of the Gamma Phage Assay was first developed by the Centers for Disease Control and Prevention (CDC) in the mid-1950s.
Aug 30, 2005, 20:56
Protective Antigen Ion Channel Asymmetric Blockade To Detect Anthrax Infection
A new laboratory method for quickly detecting active anthrax proteins within an infected blood sample at extremely low levels has been developed by researchers at the National Institute of Standards and Technology (NIST), the U.S. Army Medical Research Institute of Infectious Diseases and the National Cancer Institute.
Aug 29, 2005, 22:04
ABthrax(TM) Safe and Effective against Anthrax
Human Genome Sciences, Inc. (HGSI) announced today that results published in the current issue of Clinical Infectious Diseases demonstrate that the first investigational agent against anthrax infection to be evaluated in a clinical study since the 2001 anthrax attacks in the United States, is safe, well tolerated and achieves the blood levels predicted by relevant animal models as necessary to afford significant protection from the lethal effects of the anthrax toxin.
Jul 25, 2005, 11:13
DNI - Newly Identified Inhibitor of Anthrax Toxin May Contribute to Postexposure Therapy
A newly identified inhibitor of the anthrax toxin may be used to develop a safer and more effective vaccine and act as a therapeutic agent after exposure say researchers from Massachusetts and Germany. Their findings appear in the June 2005 issue of the journal Infection and Immunity.
Jun 20, 2005, 16:08